JCO Early Release, published online ahead of print Oct 30 2006
Journal of Clinical Oncology, 10.1200/JCO.2005.04.1152
Received September 4, 2005
Accepted September 15, 2006
Palifermin Reduces the Incidence of Oral Mucositis in Patients With Metastatic Colorectal Cancer Treated With Fluorouracil-Based Chemotherapy
Lee S. Rosen,* Ehtesham Abdi, Ian D. Davis, John Gutheil, Frederick M. Schnell, John Zalcberg, Alessandra Cesano, Urte Gayko, Mon-Gy Chen, and Stephen Clarke
From Premiere Oncology, John Wayne Cancer Institute, St John's Health Center, Santa Monica; Sharp HealthCare, Sidney Kimmel Cancer Center, San Diego; Amgen Inc, Thousand Oaks, CA; Bendigo Health Care Group, Bendigo; Department of Medical Oncology, Austin Health, Heidelberg; Peter MacCallum Cancer Institute, Melbourne, Victoria; Medical Oncology Department, Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia; and Central Georgia Hematology Oncology, Macon, GA.
* To whom correspondence should be addressed. E-mail: lrosen{at}premiereoncology.com
Purpose: To characterize the efficacy and safety of palifermin in reducing the incidence of oral mucositis (OM) and diarrhea when administered to patients with metastatic colorectal cancer (CRC) receiving fluorouracil/leucovorin (FU/LV) chemotherapy.
Patients and Methods: Patients (N = 64) were randomly assigned to receive either placebo or palifermin (40 µg/kg for 3 consecutive days) before each of two consecutive cycles of chemotherapy with FU/LV. The incidence of OM and diarrhea, safety, disease progression, and survival were evaluated.
Results: Thirty-six patients received placebo and 28 patients received palifermin. The incidence of WHO grade 2 or higher OM was lower in patients who received palifermin compared with placebo (29% v 61% in cycle 1; 11% v 47% in cycle 2). FU dose reductions in the second chemotherapy cycle were more frequent in the placebo group (31%) than in the palifermin group (14%). Investigators reported lower mucositis scores and patients reported less severe symptoms with palifermin. There were no statistically significant differences in the incidence or severity of diarrhea or in overall survival between the groups. Overall, palifermin was safe and well tolerated.
Conclusion: Palifermin administered at the indicated dosing regimen (40 µg/kg for 3 consecutive days) before chemotherapy was well tolerated and resulted in a statistically significant and clinically meaningful reduction in the incidence of WHO grade 2 or higher OM in patients with metastatic CRC.
 CiteULike  Complore  Connotea  Del.icio.us  Digg  Facebook  Reddit  Technorati  Twitter What's this?
Related Correspondence
- Questions About the Role of Palifermin in Fluorouracil-Based Therapy for Metastatic Colorectal Cancer
Ian E. Haines
JCO 2007 25: 24-25
[Full Text]
This article has been cited by other articles:
|
|
|
|
 
D. E. Peterson, N. P. Barker, L. I. Akhmadullina, I. Rodionova, N. Z. Sherman, I. S. Davidenko, G. N. Rakovskaya, E. A. Gotovkin, S. A. Shinkarev, M. V. Kopp, et al.
Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Recombinant Human Intestinal Trefoil Factor Oral Spray for Prevention of Oral Mucositis in Patients With Colorectal Cancer Who Are Receiving Fluorouracil-Based Chemotherapy
J. Clin. Oncol.,
September 10, 2009;
27(26):
4333 - 4338.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. E. Peterson, R.-J. Bensadoun, F. Roila, and On behalf of the ESMO Guidelines Working Group
Management of oral and gastrointestinal mucositis: ESMO Clinical Recommendations
Ann. Onc.,
May 1, 2009;
20(suppl_4):
iv174 - iv177.
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. L. Hensley, K. L. Hagerty, T. Kewalramani, D. M. Green, N. J. Meropol, T. H. Wasserman, G. I. Cohen, B. Emami, W. J. Gradishar, R. B. Mitchell, et al.
American Society of Clinical Oncology 2008 Clinical Practice Guideline Update: Use of Chemotherapy and Radiation Therapy Protectants
J. Clin. Oncol.,
January 1, 2009;
27(1):
127 - 145.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. Schmidt, N. H. Thoennissen, A. Rudat, R. Bieker, C. Schliemann, R. M. Mesters, M. Zuhlsdorf, C. Muller-Tidow, and W. E. Berdel
Use of palifermin for the prevention of high-dose methotrexate-induced oral mucositis
Ann. Onc.,
September 1, 2008;
19(9):
1644 - 1649.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Brake, C. Starnes, J. Lu, D. Chen, S. Yang, R. Radinsky, and L. Borges
Effects of Palifermin on Antitumor Activity of Chemotherapeutic and Biological Agents in Human Head and Neck and Colorectal Carcinoma Xenograft Models
Mol. Cancer Res.,
August 1, 2008;
6(8):
1337 - 1346.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. R. Zalcberg, L. S. Rosen, E. Abdi, I. D. Davis, J. Gutheil, F. M. Schnell, A. Cesano, U. Gayko, M.-G. Chen, and S. Clarke
Role of Palifermin in Fluorouracil-Based Therapy for Metastatic Colorectal Cancer
J. Clin. Oncol.,
March 10, 2008;
26(8):
1386 - 1387.
[Full Text]
[PDF]
|
|
|
|
